Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients
Tuesday, October 24, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a poster presentation on a Phase 2 clinical trial of CT1812, focusing on identifying pharmacodynamic biomarkers in cerebrospinal fluid (CSF) and plasma, as well as molecular correlates of EEG in Alzheimer's patients. This research was presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts, in October 2023.
Price reaction · baseline $1.24 (2023-10-23 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
-1.6%
Market Sentiment Analysis
POSITIVE FACTORS
CT1812 is being studied for its potential in Alzheimer's treatment.
The trial aims to identify important biomarkers for Alzheimer's.
The research is presented at a notable conference, CTAD.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Di Caro V, Pandey K, Lizama B, et al. Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients . Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD) ; Boston, Massachusetts.
Frequently Asked Questions
What is the focus of the CT1812 clinical trial?
The trial focuses on identifying pharmacodynamic biomarkers in Alzheimer's patients.
Where was the CT1812 trial presented?
The trial was presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference.
What types of biomarkers are being studied?
The study examines biomarkers in cerebrospinal fluid (CSF) and plasma.